Neuroprotective effects and dynamic expressions of MMP9 and TIMP1 associated with atorvastatin pretreatment in ischemia–reperfusion rats. (31st August 2015)

• Record Type: Journal Article
• Authors: Fang, Xiao; Tao, Dingbo; Shen, Jingshun; Wang, Yingxin; Dong, Xiang; Ji, Xiaofei
• Is Part Of: Neuroscience letters. Volume 603(2015)
• Page Start: 60
• Page End: 65
• Publication Date: 2015-08-31
• Subjects: Atorvastatin -- Ischemia–reperfusion -- MMP9 -- TIMP1 -- Rats -- MCAo -- Pretreatment; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2015.07.013
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: Neuroprotective effects and dynamic expressions of MMP9 and TIMP1 associated with atorvastatin pretreatment in ischemia–reperfusion rats. Atorvastatin can lower MMP9 levels and elevates TIMP1 levels in I/R injury. Atorvastatin can reduce the severity in I/R injury and improve neurological outcome. It's nueroprotective role is related to the dynamic expressions of MMP9 and TIMP1 Abstract: Atorvastatin has been reported to ameliorate ischemic brain damage after stroke, but the underlying mechanisms are not clear. This study investigated the effect of atorvastatin on dynamic expressions of MMP9 and TIMP1 in rats after cerebral ischemia reperfusion (I/R). Atorvastatin (5 mg kg −1 d −1 ) or vehicle was administered orally to rats for 21d before middle cerebral artery occlusion (MCAo) for 2 h, with perfusion at 3-, 12-, 24-, 48-, or 96-h thereafter. To evaluate functional outcome, a 5-point behavioral rating scale was performed. Ischemic lesion volume was assessed via triphenyl tetrazolium chloride (TTC) staining. mRNA levels of MMP-9 and TIMP-1 were detected by reverse transcription-PCR, and protein levels of MMP-9 and TIMP-1 were measured by immunohistochemical SABC method. At all reperfusion time points, atorvastatin pretreatment was associated with significantly ( P < 0.05) improved neurological function and reduced brain infarct sizes compared with vehicle treatment, and MMP9 levels were significantly ( P < 0.05) lower and TIMP1 levels were significantly ( P < 0.05) higher in both mRNA and protein levels. In conclusion, Oral administration of atorvastatin before stroke may reduce the severity in I/R injury and improve neurological outcome by lowering MMP9 levels and elevating TIMP1 levels.